Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Boundless Bio, Inc. (BOLD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.82, with a market capitalisation of $64.60M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.96 to $3.16. This page covers its latest market performance, valuation, price trends and company information.
$64.60M | |
$2.83 | |
$60.00 | |
$0.96 | |
$2.84 | |
22.63K | |
1.28M | |
-- | |
$3.16 | |
$0.96 | |
-- | |
-- |
Boundless Bio, Inc. (BOLD) is trading at $2.85 in pre-market trading as of 2026-09-15 22:37:00, up 0.35% ($0.01) from the previous close of $2.84
Pre-market trading shows how investors are pricing BOLD before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Boundless Bio, Inc. (BOLD) moved from $2.87 to $2.82, representing a decline of 1.74% ($0.05).
The stock traded between $2.76 and $2.94 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 54.63 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.4%
BOLD is currently trading at $2.82, placing it 84.4% of the way from its 52-week low of $0.96 to its 52-week high of $3.16. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Boundless Bio, Inc. (BOLD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.